AstraZeneca BD Head Says More Out-Licensing, Divestment Expected In 2016

AstraZeneca PLC says it remains committed to developing medicines across small molecules, biologics, vaccines, protein engineering and devices and that's what its future targeted business development strategy will pursue.

AstraZeneca PLC says it remains committed to developing medicines across small molecules, biologics, vaccines, protein engineering and devices and that's what its future targeted business development strategy will pursue.

Britain's second-biggest drug maker has recently been selling mature products to buyers in efforts to focus on its central...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category